期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
示踪甲状腺乳头状癌侧颈淋巴结的前瞻性研究 被引量:9
1
作者 黄乃思 马奔 +9 位作者 官青 王蕴珺 周力 魏文俊 卢忠武 杨舒雯 徐伟博 向俊 嵇庆海 王宇 《中国肿瘤临床》 CAS CSCD 北大核心 2018年第20期1053-1056,共4页
目的:探索在甲状腺乳头状癌中纳米炭示踪侧颈部淋巴结的应用价值。方法:前瞻性地入组2016年3月至2017年11月复旦大学附属肿瘤医院接受甲状腺癌手术患者,术前超声或CT提示侧颈部淋巴结可疑转移,术中应用纳米炭混悬注射液进行侧颈部淋巴... 目的:探索在甲状腺乳头状癌中纳米炭示踪侧颈部淋巴结的应用价值。方法:前瞻性地入组2016年3月至2017年11月复旦大学附属肿瘤医院接受甲状腺癌手术患者,术前超声或CT提示侧颈部淋巴结可疑转移,术中应用纳米炭混悬注射液进行侧颈部淋巴结示踪。结果:共67例患者接受了70例/侧颈部淋巴结示踪手术,侧颈部淋巴结转移57例(81.4%)。炭阳性淋巴结的中位检出数量为6枚。Ⅳ区炭染淋巴结无论在送检例数、送检淋巴结枚数以及转移淋巴结比例均为最高。Ⅲ~Ⅳ区淋巴结中炭阳性淋巴结的转移比例显著高于炭阴性淋巴结(P<0.001)。将最终颈清扫结果作为金标准,计算Ⅲ~Ⅳ区炭阳性淋巴结活检敏感度为86.0%。结论:纳米炭是甲状腺癌侧颈部淋巴结示踪的潜在方法。联合侧颈部Ⅲ~Ⅳ区炭阳性淋巴结活检,可以达到较高的敏感度,是较为合理的前哨淋巴结活检范围。 展开更多
关键词 甲状腺乳头状癌 侧颈部淋巴结 淋巴结示踪 颈清扫 前哨淋巴结活检
下载PDF
2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma 被引量:29
2
作者 Ming Gao Minghua Ge +26 位作者 qinghai ji Ruochuan Cheng Hankui Lu Haixia Guan Li Gao Zhuming Guo Tao Huang Xiaoming Huang Xiaoming Li Yansong Lin Qinjiang Liu Xin Ni Yi Pan jianwu Qin Zhongyan Shan Hui Sun Xudong Wang Zhengang Xu Yang Yu Daiwei Zhao Naisong Zhang ShengZhang Ying Zheng jingqiang Zhu Dapeng Li Xiangqian Zheng 《Cancer Biology & Medicine》 SCIE CAS CSCD 2017年第3期203-211,共9页
The incidence of papillary thyroid carcinoma(PTC)has exponentially increased in recent years.Papillary thyroid microcarcinoma(PTMC)accounts for the majority of the reported cases of PTC.The debates and crucial issues ... The incidence of papillary thyroid carcinoma(PTC)has exponentially increased in recent years.Papillary thyroid microcarcinoma(PTMC)accounts for the majority of the reported cases of PTC.The debates and crucial issues in PTMC management have received researchers'attention.To further improve the clinical management of PTMC in China, 展开更多
关键词 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
下载PDF
2017 Chinese expert consensus on the clinical application ofserum marker for thyroid cancer 被引量:4
3
作者 Ming Gao Minghua Ge +26 位作者 qinghai ji Ruochuan Cheng Hankui Lu Haixia Guan Wei Cui Li Gao Zairong Gao Lin Guo Zhuming Guo Tao Huang Xiaoming Huang Yansong Lin Qinjiang Liu Xin Ni jianwu Qin Li Ren Zhongyan Shan Hui Sun Xudong Wang Zhengang Xu Yang Yu Bin Zhang DaiweiZhao Ying Zheng jingqiang Zhu Xiangqian Zheng 《Cancer Biology & Medicine》 SCIE CAS CSCD 2018年第4期468-477,共10页
In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There ar... In recent years, the clinical incidence of thyroid cancer has been increasing year by year, and its risk assessment and clinical management methods have also been accordingly modified and constantly improved. There are great differences between the clinical diagnostic and therapeutic modes and disease management of thyroid cancer employed by various medical institutions in China, particularly with regard to the clinical application of serum marker of thyroid cancer. To this end, the China Anti-Cancer Association Thyroid Cancer Specialized Committee Chinese Association of Thyroid Oncology organized this compilation of ExpertConsensus on Clinical Application of Serum Marker of Thyroid Cancer to help and impel relevant clinical institutions and professionals to standardize clinical diagnosis, treatment, and long-term management of thyroid cancer, and to properly utilize the serum marker for scientific auxiliary clinical diagnosis and assessment of thyroid cancer before and after operation. 展开更多
关键词 Chinese expert consensus on the clinical application of serum marker for thyroid cancer MTC TG
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部